Originating from Aarhus University, PulmoPharma has garnered support for its innovative Puldium™ research, showing promise against resistant Aspergillus fumigatus. Catering to patients with azole-resistant infections and ABPA, they’re conducting pre-clinical studies to secure approval for human trials. The company is on the lookout for partnerships with key medical entities.
Established in 2014.
